Literature DB >> 12058260

A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein.

X B Wang1, X Zhao, R Giscombe, A K Lefvert.   

Abstract

CTLA-4 is an important negative regulator of the immune system. The regulation of the CTLA-4 gene (Ctla-4) transcription is poorly understood. A single nucleotide polymorphism (SNP) at -318 in the Ctla-4 promoter region is associated with certain autoimmune diseases. Since the -318 SNP occurs in a potential regulatory region, it is conceivable that the C' T transition may affect the expression of Ctla-4. In the present study, we show that the -318T allele is associated with a higher promoter activity than the -318C allele (8.13 +/- 0.46 vs 6.87 +/- 0.49). The presence of the -318T allele may thus contribute to up regulation of the expression of CTLA-4, and consequently represent one mechanism to inhibit exaggerated immune activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12058260     DOI: 10.1038/sj.gene.6363869

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  54 in total

1.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

2.  Association of CT60 cytotoxic T lymphocyte antigen-4 gene polymorphism with thyroid autoantibody production in patients with Hashimoto's and postpartum thyroiditis.

Authors:  K Zaletel; B Krhin; S Gaberscek; A Bicek; T Pajic; S Hojker
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

3.  Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: a meta-analysis.

Authors:  Hong-Bing Xu; Huan Yang; Tingting Liu; Hong Chen
Journal:  Tumour Biol       Date:  2014-02

Review 4.  Autoimmune effector memory T cells: the bad and the good.

Authors:  Priyadharshini Devarajan; Zhibin Chen
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 5.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Rodrigo Cartin-Ceba; Tobias Peikert; Ulrich Specks
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

6.  Association between CTLA-4 + 49A > G and - 318C > T single-nucleotide polymorphisms and susceptibility to thyroid neoplasm.

Authors:  Shabnam Abtahi; Fatemeh Izadi Jahromi; Mohammad Hossein Dabbaghmanesh; Mahyar Malekzadeh; Abbas Ghaderi
Journal:  Endocrine       Date:  2018-08-04       Impact factor: 3.633

Review 7.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 8.  The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.

Authors:  Lisa C Willcocks; Paul A Lyons; Andrew J Rees; Kenneth G C Smith
Journal:  Arthritis Res Ther       Date:  2010-02-15       Impact factor: 5.156

9.  Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis.

Authors:  G Balbi; F Ferrera; M Rizzi; P Piccioli; A Morabito; L Cardamone; M Ghio; G L Palmisano; P Carrara; S Pedemonte; M Sessarego; M De Angioletti; R Notaro; F Indiveri; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2007-04-25       Impact factor: 4.330

10.  Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

Authors:  Marna G Bouwhuis; Andreas Gast; Adina Figl; Alexander M M Eggermont; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Cancer Immunol Immunother       Date:  2010-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.